Literature DB >> 9055139

Effect of acute phase response on phenytoin metabolism in neurotrauma patients.

D S McKindley1, B A Boucher, M M Hess, J H Rodman, C Feler, T C Fabian.   

Abstract

The purpose of this prospective study was to correlate measures of the acute phase response, associated therapeutic interventions, and other clinical variables with the process of altered drug metabolism previously observed in patients with severe neurotrauma. Nine patients with severe head injury (Glasgow Coma Scale < or = 8) requiring intravenous phenytoin were included in the study. A loading dose of phenytoin was followed by daily maintenance doses. Serial blood samples were taken after the loading dose and every even-numbered study day for 10 to 14 days for measurement of total and unbound concentrations of phenytoin, interleukin-1 beta, interleukin-6 (IL-6), tumor necrosis factor alpha, alpha 1-acid-glycoprotein, C-reactive protein, and albumin. Time-invariant and time-variant Michaelis-Menten models were fit to the phenytoin concentration-time data. Protein intake was closely monitored. The mean (+/- SEM) unbound fraction of phenytoin increased from 0.17 +/- 0.02 on day 1 to 0.24 +/- 0.04 on day 10 (P < 0.05). The time-variant model was superior in describing the concentration-time data of unbound phenytoin in eight of nine patients. Mean (+/- SEM) pharmacokinetic parameter estimates for unbound phenytoin were: Vmax delta = 605 +/- 92 mg/day, VmaxB = 149 +/- 26.3 mg/day, K(ind) = 0.013 +/- 0.004 hr-1. Interleukin-6 was the only cytokine with significant concentration changes over time; it was inversely correlated with Vmax,t. Peak concentrations of interleukin-6 also proved to be inversely correlated with VmaxB. The daily amount of protein administered was significantly correlated with Vmax,t. Significant alterations in the metabolism of phenytoin occur after severe neurotrauma. The etiology of these changes is probably multifaceted. These results suggest that low initial phenytoin Vmax may be explained by the presence of interleukin-6. An increase in oxidative metabolism that correlated with nutritional protein administration was observed later in these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055139     DOI: 10.1002/j.1552-4604.1997.tb04771.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Pharmacokinetics of phenytoin: reminders and discoveries.

Authors:  Donna C Bergen
Journal:  Epilepsy Curr       Date:  2009 Jul-Aug       Impact factor: 7.500

3.  Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.

Authors:  Gail D Anderson; Nancy R Temkin; Asaad B Awan; H Richard Winn; Richard H Winn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Retrospective analysis of levetiracetam compared to phenytoin for seizure prophylaxis in adults with traumatic brain injury.

Authors:  G Christina Caballero; Darrel W Hughes; Pamela R Maxwell; Kay Green; Conrado D Gamboa; Colleen A Barthol
Journal:  Hosp Pharm       Date:  2013-10

Review 5.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

6.  Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury.

Authors:  Philip E Empey; Nieves Velez de Mendizabal; Michael J Bell; Robert R Bies; Kacey B Anderson; Patrick M Kochanek; P David Adelson; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

Review 7.  Novel therapeutic strategies for traumatic brain injury: acute antioxidant reinforcement.

Authors:  Rodrigo Fernández-Gajardo; José Manuel Matamala; Rodrigo Carrasco; Rodrigo Gutiérrez; Rómulo Melo; Ramón Rodrigo
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 8.  Antiepileptic drugs in critically ill patients.

Authors:  Salia Farrokh; Pouya Tahsili-Fahadan; Eva K Ritzl; John J Lewin; Marek A Mirski
Journal:  Crit Care       Date:  2018-06-07       Impact factor: 9.097

9.  Variability of serum phenytoin levels in critically ill head injured patients in intensive care unit.

Authors:  Lalitha V Pillai; Narendra Vaidya; A D Khade; Saiffuddin Hussainy
Journal:  Indian J Crit Care Med       Date:  2008-01

Review 10.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.